The Recall Desk
Agency classClass IIOur severity:HighFDA (Drugs)·D-1058-2023·Announced 2023-08-09

HYDROmorphone Injection Recall Due to Sterility Assurance Failure

Central Admixture Pharmacy Services is recalling 2,077 syringes of HYDROmorphone injection (15 mg/30 mL) distributed nationwide due to lack of validation data for sanitization cycles. No adverse events have been reported.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 3/5 (High).

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: This is an FDA Class II recall without reported illnesses or injuries. The hazard—lack of sterility assurance due to inadequate sanitization validation—represents a potential risk to patients, meeting the rubric criterion for 'risk-of-harm products where injury has not yet been reported.'

Plain-English summary

Central Admixture Pharmacy Services Inc. is recalling 2,077 syringes of HYDROmorphone in 0.9% sodium chloride (15 mg/30 mL, 0.5 mg/mL) supplied as 30 mL syringes distributed nationwide in the USA. The product is a prescription injectable opioid medication (NDC 71286-2011-1).

The recall was initiated due to lack of assurance of sterility. The manufacturer lacked adequate validation data for the sanitization cycles used in production. Sterile injectable products require documented proof that sterilization and sanitization processes are effective and reliable.

The affected lots are: 17-270770 (Exp. 7/19/2023), 17-271061 (Exp. 7/24/2023), 17-271419 (Exp. 7/30/2023), 17-271678 (Exp. 8/2/2023), 17-272124 (Exp. 8/10/2023), 17-272302 (Exp. 8/14/2023), 17-272518 (Exp. 8/17/2023), 17-273493 (Exp. 9/4/2023), and 17-273671 (Exp. 9/6/2023). Healthcare providers and patients should consult their healthcare provider if they have received this product. The FDA has not received any adverse event reports related to this recall.

The recalled product

Product
HYDROmorphone in 0.9% sodium chloride, 15 mg/30 mL, (0.5 mg/mL), 30 mL Syringe, Rx only, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC 71286-2011-1
Manufacturer
Central Admixture Pharmacy Services Inc
Category
Drug — Injectable / Opioid
Hazard
Affected units
2,077

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (18)

  • Lot: 17-270770
  • Exp. 7/19/2023
  • 17-271061
  • Exp. 7/24/2023
  • 17-271419
  • Exp. 7/30/2023
  • 17-271678
  • Exp. 8/2/2023
  • 17-272124
  • Exp. 8/10/2023
  • 17-272302
  • Exp. 8/14/2023
  • 17-272518
  • Exp. 8/17/2023
  • 17-273493
  • Exp. 9/4/2023
  • 17-273671
  • Exp. 9/6/2023.

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 39 products in this recall →

Related recalls

Same manufacturer · Central Admixture Pharmacy Services Inc

See all →

Same hazard · contamination

See all →

Similar recalls